{"title":"Metabolic \u0026 Weight","description":"Peptides investigated across metabolic research fields, including GLP receptor agonism, mitochondrial biogenesis, and body composition pathways. Features Retatrutide, Tirzepatide, MOTS-c, 5-Amino-1MQ, and SLU-PP-332. For research use only.","products":[{"product_id":"retatrutide","title":"Reta GLP3","description":"\u003cp dir=\"auto\"\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e (also known as \u003cstrong\u003eLY3437943\u003c\/strong\u003e) is a \u003cstrong\u003esynthetic\u003c\/strong\u003e long-acting \u003cstrong\u003epeptide\u003c\/strong\u003e engineered as a triple agonist of the glucagon receptor (\u003cstrong\u003eGCGR\u003c\/strong\u003e), glucose-dependent insulinotropic polypeptide receptor (\u003cstrong\u003eGIPR\u003c\/strong\u003e), and glucagon-like peptide-1 receptor (\u003cstrong\u003eGLP-1R\u003c\/strong\u003e). This research compound has generated substantial scientific interest for its potential in modulating energy metabolism, appetite regulation, and glucose homeostasis. Preliminary and advanced preclinical studies, along with emerging clinical data, indicate that retatrutide may induce significant weight reduction, improve glycemic control, enhance lipid profiles, and promote liver fat reduction through synergistic activation of these incretin and glucagon pathways. Researchers employ this peptide in laboratory and animal models to investigate mechanisms of obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and related metabolic disorders. As a research-grade compound, retatrutide is intended exclusively for in vitro and animal studies. Scientists value its balanced potency profile across the three receptors and its utility in advancing understanding of multi-receptor agonism in metabolic regulation.\u003c\/p\u003e\n\u003ch3 dir=\"auto\"\u003eKey Research Applications\u003c\/h3\u003e\n\u003cul dir=\"auto\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eObesity and Weight Management\u003c\/strong\u003e — Preclinical models demonstrate that retatrutide markedly reduces body weight through decreased food intake, delayed gastric emptying, and increased energy expenditure. Studies show superior efficacy compared to dual agonists, with substantial fat mass loss and preservation of lean mass in various obesity models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlycemic Control and Type 2 Diabetes\u003c\/strong\u003e — Retatrutide enhances glucose-dependent insulin secretion, improves insulin sensitivity, and lowers fasting glucose and HbA1c levels in diabetic and prediabetic models. Its triple agonism supports better metabolic outcomes than single or dual incretin therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLiver Health and MASLD\/MASH\u003c\/strong\u003e — Investigations reveal potent reductions in liver fat content, improvements in steatosis, and modulation of fibrosis markers. Preclinical and early clinical data highlight its role in reversing metabolic dysfunction-associated steatotic liver disease through combined effects on lipid metabolism and inflammation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLipid Metabolism and Cardiovascular Support\u003c\/strong\u003e — Retatrutide favorably alters lipid profiles by reducing triglycerides, LDL, and VLDL while promoting fat oxidation and ketone body production. Research explores its potential benefits in mitigating obesity-related cardiovascular risk factors.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBroader Metabolic and Oncologic Implications\u003c\/strong\u003e — Emerging studies suggest protective effects against obesity-associated cancer progression, with reduced tumor growth and immune reprogramming in preclinical tumor models, potentially linked to sustained weight loss and metabolic improvements.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 dir=\"auto\"\u003eTechnical Specifications\u003c\/h3\u003e\n\u003cul dir=\"auto\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular Formula\u003c\/strong\u003e: C₂₂₁H₃₄₂N₄₆O₆₈\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e: 4731.3 g\/mol\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSequence\u003c\/strong\u003e: Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-(α-Me-Leu)-Leu-Asp-Lys-[side chain modified Lys]-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ (Where Aib = 2-aminoisobutyric acid; α-Me-Leu = 2-methylleucine; includes a C20 fatty diacid-γ-Glu-AEEA linker on a lysine residue for extended half-life)\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Omni Peptides","offers":[{"title":"10mg","offer_id":50413231276279,"sku":"RT10","price":700.0,"currency_code":"AED","in_stock":true},{"title":"30mg","offer_id":50413231309047,"sku":"RT30","price":1400.0,"currency_code":"AED","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0918\/6777\/5223\/files\/reta.png?v=1768028138"},{"product_id":"mots-c","title":"MOTS-c","description":"\u003cp\u003e\u003cspan\u003eClean GH boost, recovery, fat metabolism\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"auto\"\u003e\u003cstrong\u003eMOTS-c\u003c\/strong\u003e (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a \u003cstrong\u003esynthetic version\u003c\/strong\u003e of the naturally occurring 16-amino-acid \u003cstrong\u003emitochondrial-derived peptide\u003c\/strong\u003e (MDP) encoded by a short open reading frame within the mitochondrial 12S rRNA gene (MT-RNR1). This research compound has attracted significant scientific interest for its role as a \u003cstrong\u003emetabolic regulator\u003c\/strong\u003e and \u003cstrong\u003eexercise mimetic\u003c\/strong\u003e. Preliminary and advanced preclinical studies indicate that MOTS-c may activate AMP-activated protein kinase (AMPK), enhance glucose uptake in skeletal muscle, promote metabolic flexibility, reduce insulin resistance, and support mitochondrial biogenesis. Researchers utilize this peptide in laboratory and animal models to explore mechanisms of energy homeostasis, particularly in models of obesity, type 2 diabetes, aging, and exercise physiology. As a research-grade compound, MOTS-c is intended exclusively for in vitro and animal studies. Scientists value its unique mitochondrial origin, systemic hormonal-like actions, and potential to elucidate mitochondrial-nuclear communication in metabolic health.\u003c\/p\u003e\n\u003ch3 dir=\"auto\"\u003eKey Research Applications\u003c\/h3\u003e\n\u003cul dir=\"auto\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMetabolic Homeostasis and Insulin Sensitivity\u003c\/strong\u003e — Preclinical investigations show that MOTS-c improves insulin sensitivity, enhances glucose uptake in skeletal muscle via the folate-AICAR-AMPK pathway, and counters high-fat diet-induced insulin resistance and obesity in various models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExercise Mimetic Effects\u003c\/strong\u003e — MOTS-c is upregulated in response to exercise and mimics many of its benefits, including increased energy expenditure, improved physical performance, and metabolic adaptations in skeletal muscle, with enhanced endurance observed in aged and obese animal models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eObesity and Weight Management\u003c\/strong\u003e — Studies demonstrate that MOTS-c reduces body weight gain, promotes fat oxidation, and prevents diet-induced obesity through modulation of lipid metabolism and thermogenesis in adipose tissue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAging and Longevity Support\u003c\/strong\u003e — Research highlights its role in counteracting age-related metabolic decline, improving muscle function, and potentially extending healthspan by enhancing mitochondrial stress responses and reducing oxidative damage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBroader Protective Effects\u003c\/strong\u003e — Investigations suggest benefits in bone metabolism regulation (promoting osteoblast activity and inhibiting osteoclastogenesis), liver health (reducing steatosis in NAFLD models), anti-inflammatory actions, and protection against metabolic stress in various organ systems.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 dir=\"auto\"\u003eTechnical Specifications\u003c\/h3\u003e\n\u003cul dir=\"auto\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular Formula\u003c\/strong\u003e: C₁₀₁H₁₅₂N₂₈O₂₂S₂\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e: 2174.6 g\/mol\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSequence\u003c\/strong\u003e: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Omni Peptides","offers":[{"title":"10mg","offer_id":50413243433207,"sku":"MS10","price":300.0,"currency_code":"AED","in_stock":true},{"title":"40mg","offer_id":50413243465975,"sku":"MS40","price":980.0,"currency_code":"AED","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0918\/6777\/5223\/files\/motsc.png?v=1768028138"},{"product_id":"tesamorelin","title":"Tesamorelin","description":"\u003cp\u003e\u003cspan\u003eGHRH analog; strongest visceral\/abdominal fat burner, clean GH\/IGF-1 boost\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"auto\"\u003e\u003cstrong\u003eTesamorelin\u003c\/strong\u003e (also known as \u003cstrong\u003eTH9507\u003c\/strong\u003e) is a \u003cstrong\u003esynthetic 44-amino-acid polypeptide\u003c\/strong\u003e analog of human \u003cstrong\u003egrowth hormone-releasing hormone\u003c\/strong\u003e (\u003cstrong\u003eGHRH\u003c\/strong\u003e), featuring an N-terminal modification with a \u003cstrong\u003etrans-3-hexenoyl\u003c\/strong\u003e group for enhanced stability and resistance to enzymatic degradation. This research compound has garnered significant scientific interest for its ability to stimulate pulsatile endogenous \u003cstrong\u003egrowth hormone\u003c\/strong\u003e (\u003cstrong\u003eGH\u003c\/strong\u003e) secretion from the anterior pituitary, thereby elevating \u003cstrong\u003einsulin-like growth factor-1\u003c\/strong\u003e (\u003cstrong\u003eIGF-1\u003c\/strong\u003e) levels and influencing metabolic pathways. Preliminary and advanced preclinical studies indicate that tesamorelin may promote lipolysis, reduce visceral adipose tissue, support muscle preservation, and modulate body composition. Researchers employ this peptide in laboratory and animal models to investigate mechanisms of GH axis regulation, fat metabolism, and endocrine responses, particularly in models of metabolic dysregulation and age-related decline. As a research-grade compound, tesamorelin is intended exclusively for in vitro and animal studies. Scientists value its improved pharmacokinetic profile over native GHRH and its utility in elucidating targeted GH stimulation without direct exogenous hormone administration.\u003c\/p\u003e\n\u003ch3 dir=\"auto\"\u003eKey Research Applications\u003c\/h3\u003e\n\u003cul dir=\"auto\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eVisceral Adipose Tissue Reduction\u003c\/strong\u003e — Preclinical and clinical-model studies demonstrate that tesamorelin significantly decreases visceral fat accumulation through enhanced lipolysis and triglyceride reduction. It has been extensively investigated in models of HIV-associated lipodystrophy and central obesity, showing preferential effects on abdominal fat while preserving subcutaneous adipose tissue.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGrowth Hormone Axis Stimulation\u003c\/strong\u003e — Tesamorelin potently activates GHRH receptors to induce pulsatile GH release and elevate IGF-1 levels. Research explores its role in restoring GH secretion in states of relative deficiency, including aging, metabolic syndrome, and antiretroviral therapy-related endocrine disruption.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBody Composition and Muscle Health\u003c\/strong\u003e — Investigations reveal tesamorelin's potential to increase lean muscle area and density in truncal muscle groups, while improving muscle quality metrics (e.g., Hounsfield units) in models of sarcopenia and fat infiltration. Studies assess its anabolic effects alongside fat loss for better overall body composition.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMetabolic and Lipid Profile Modulation\u003c\/strong\u003e — Tesamorelin favorably influences lipid metabolism, insulin sensitivity, and energy balance in preclinical models. Research examines its impact on triglycerides, liver fat, and metabolic parameters in obesity and diabetes-related contexts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBroader Endocrine and Protective Effects\u003c\/strong\u003e — Emerging studies probe its applications in neuroprotection, cardiovascular health, and age-related metabolic decline, with implications for investigating GH-mediated anabolic and lipolytic pathways across multiple organ systems.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 dir=\"auto\"\u003eTechnical Specifications\u003c\/h3\u003e\n\u003cul dir=\"auto\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular Formula\u003c\/strong\u003e: C₂₂₁H₃₆₆N₇₂O₆₇S\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e: 5135.9 g\/mol (free base)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSequence\u003c\/strong\u003e: trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂ (C-terminal amidation)\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Omni Peptides","offers":[{"title":"10mg","offer_id":50413275873527,"sku":"TSM10","price":500.0,"currency_code":"AED","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0918\/6777\/5223\/files\/ts-10mg.png?v=1768028138"},{"product_id":"tirzepatide-glp2","title":"Tirz GLP2","description":"\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cp dir=\"auto\" style=\"white-space: pre-wrap;\"\u003e\u003cstrong\u003eTirzepatide\u003c\/strong\u003e is a \u003cstrong\u003esynthetic dual-incretin peptide\u003c\/strong\u003e engineered as a balanced agonist of both the \u003cstrong\u003eglucose-dependent insulinotropic polypeptide receptor\u003c\/strong\u003e (\u003cstrong\u003eGIPR\u003c\/strong\u003e) and the \u003cstrong\u003eglucagon-like peptide-1 receptor\u003c\/strong\u003e (\u003cstrong\u003eGLP-1R\u003c\/strong\u003e). This research compound has garnered exceptional scientific interest for its potent effects on \u003cstrong\u003eglucose homeostasis\u003c\/strong\u003e, \u003cstrong\u003eappetite regulation\u003c\/strong\u003e, and \u003cstrong\u003ebody weight reduction\u003c\/strong\u003e. Preclinical and emerging clinical-model studies demonstrate that tirzepatide induces significant weight loss, improves glycemic control, enhances insulin sensitivity, and favorably modulates lipid metabolism through synergistic GIP and GLP-1 receptor activation. Researchers utilize this peptide in laboratory and animal models to investigate mechanisms of multi-receptor incretin signaling, metabolic syndrome, obesity, type 2 diabetes, and related comorbidities such as non-alcoholic steatohepatitis (NASH\/MASLD). As a research-grade compound, tirzepatide is intended exclusively for in vitro and animal studies. Scientists value its superior efficacy profile compared to single GLP-1R agonists and its utility in advancing understanding of combined GIP\/GLP-1 pathway activation in metabolic regulation.\u003c\/p\u003e\n\u003ch3 dir=\"auto\"\u003eKey Research Applications\u003c\/h3\u003e\n\u003cul dir=\"auto\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eObesity and Weight Management\u003c\/strong\u003e — Preclinical models show tirzepatide produces substantial, dose-dependent reductions in body weight through decreased food intake, delayed gastric emptying, increased energy expenditure, and preferential loss of fat mass while largely preserving lean mass. Studies frequently report greater weight loss than single incretin therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlycemic Control and Type 2 Diabetes\u003c\/strong\u003e — Tirzepatide markedly lowers fasting and postprandial glucose, HbA1c, and improves insulin sensitivity via enhanced glucose-dependent insulin secretion and suppressed glucagon release. Research explores its superiority in diabetic animal models and its role in β-cell protection and function.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLiver Health and MASLD\/MASH\u003c\/strong\u003e — Investigations reveal potent reductions in hepatic fat content, improvements in steatosis, inflammation, and fibrosis markers in models of metabolic dysfunction-associated steatotic liver disease. Tirzepatide’s combined GIP\/GLP-1 effects appear particularly effective in reversing liver pathology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLipid Metabolism and Cardiovascular Risk Factors\u003c\/strong\u003e — Tirzepatide favorably alters lipid profiles, reducing triglycerides, non-HDL cholesterol, and apoB levels while increasing HDL. Studies assess its potential to mitigate obesity-related cardiovascular risk through improved endothelial function and reduced inflammation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBroader Metabolic and Systemic Effects\u003c\/strong\u003e — Emerging research examines benefits in models of polycystic ovary syndrome (PCOS), neurodegenerative diseases (potential neuroprotective effects via metabolic improvement), and obesity-associated cancer risk reduction, alongside modulation of inflammatory pathways across multiple tissues.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 dir=\"auto\"\u003eTechnical Specifications\u003c\/h3\u003e\n\u003cul dir=\"auto\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular Formula\u003c\/strong\u003e: C₂₂₅H₃₄₈N₄₈O₆₈\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e: 4813.5 g\/mol (approximate; exact mass varies slightly with salt form)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSequence\u003c\/strong\u003e: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Glu-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser (Aib = 2-aminoisobutyric acid at positions 2 and 13; C20 fatty diacid-γ-Glu-AEEA linker attached to Lys²⁰ for extended half-life; C-terminal amidation)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e","brand":"Omni Peptides","offers":[{"title":"60 mg","offer_id":50857824518391,"sku":null,"price":1000.0,"currency_code":"AED","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0918\/6777\/5223\/files\/tirz_60mg.png?v=1781331697"}],"url":"https:\/\/dubaipeptides.ae\/collections\/metabolic-weight.oembed","provider":"Dubai Peptides","version":"1.0","type":"link"}